A precise quantification of positive signal and immunophenotyping of PGF-positive cells in backtracked UCB from neonates with infant MLL-AF4+versus TEL-AML1+ B-ALL would give an answer whether our assumptions are correct and whether UCB screening for the presence of MLL-AF4 is relevant. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.